Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthriti by GBIResearch

VIEWS: 72 PAGES: 169

More Info
									         Musculoskeletal Disorders Therapeutics to 2016 -
    Introduction of Monoclonal Antibodies with First - in - class
       Mechanism of Action to Increase Treatment Options in
              Osteoporosis and Rheumatoid Arthritis
 Reference Code: GBIHC032MR                                                                                     Publication Date: OCT 2010


                                       High Growth Rate and Increasing Use of Biologics Has Made Musculoskeletal Therapeutics
Musculoskeletal disorders              Market Attractive
therapeutics market
witnessed moderate                     The global musculoskeletal therapeutics market is a fast growing market, with musculoskeletal
growth of 6.3% between                 disorders considered to be the prime factor for chronic disability in the workforce .In 2009, the
2001 and 2009. In future,              global musculoskeletal disorders therapeutics market was $26.8 billion which is forecast to grow to
the growth rate is                     $45.4 billion by 2016, showing a growth rate of 8% between 2009 and 2016. According to the
expected to be 8%                      Orthopedic Industry Report, in 2006 the prevalence of musculoskeletal disorder was 25% more
between 2009 and 2016,                 than that it was in 1996. Consequently the therapeutics market has been growing at a fast pace
primarily due to launch of             over the past years which is expected to accelerate in the coming years. However, the market will
block buster drugs and                 face a marginal decline in revenues due to the patent expiries of the prominent selling drugs such
increasing use of                      as Boniva, Celebrex, Voltaren, and Humira between the years 2009 and 2016. However, the
biologics.                             launch of blockbuster drugs such as CG5503 and Ipex along with the presence of many potential
                                       biologics in the late drug development stage will offset the decline in revenues. In addition, the
                                       increase in the incidence rates of both osteoarthritis and rheumatoid arthritis will trigger growth in
                                       the global musculoskeletal disorders therapeutics market. As a result, the market will continue to
                                       remain fast growing thereby attracting the activities of major pharmaceutical companies.
                                       Strong Pipeline And The Entry Of New Players Will Intensify The Competition
                                       The musculoskeletal disorders therapeutics market has a strong pipeline base that will support the
                                       growth of this market thereby attracting many pharmaceutical and biotechnological companies.
                                       Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are active in
                                       their pipeline for musculoskeletal disorders. One of the major activities is the development of
                                       biologics as a part of new treatment options. There are some disease modifiers also in the pipeline
                                       related to osteoarthritis that are expected to enter the market in 2018. The entry of these disease
                                       modifiers will boost the osteoarthritis market thereby bringing about further rises in the
                                       musculoskeletal disorders therapeutics market in the coming years. The rapid entry of new players
                                       will intensify the competition in this market. Hence, the presence of a highly active pipeline shows
                                       there will be strong competition in the musculoskeletal disorders therapeutics market in the coming
                                       years.




Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                            GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                 Page 1
Rheumatoid Arthritis                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                        Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline, September 2010


                                                                                                  Discovery
                                                                                                     6%
                                                                       Phase III
                                                                         23%
                                                                                                              Preclinical
                                                                                                                20%




                                                                                                              Phase I
                                                                                                               17%
                                                                        Phase II
                                                                         34%


                                        Source: GBI Research, Clinical trials.gov, company websites




                                       The Musculoskeletal Disorders Therapeutics Market is Concentrated with the Top Three
                                       Companies contributing more than 60% of the Market Share
                                       The global musculoskeletal disorders therapeutics market is dominated by three major
                                       pharmaceutical companies that account for more than 60% of the total share of this market. The
                                       major market share is occupied by Abbott, followed by Johnson & Johnson and Amgen. The
                                       presence of various large as well as small pharmaceutical companies makes this market strong in
                                       terms of competition. However, the presence of blockbuster drugs has made these three
                                       companies the dominant players in this market. Abbott with Humira, the drug for rheumatoid
                                       arthritis, stands first with total revenues of $5.5 billion. Remicade, the drug used to treat rheumatoid
                                       arthritis, has made Johnson & Johnson the second largest player in the musculoskeletal disorders
                                       therapeutics market with total revenues of $4.3 billion. Amgen, with rheumatoid arthritis drug,
                                       Enbrel occupies the third position in terms of market share with total revenues of $3.3 billion for
                                       musculoskeletal disorder therapeutics market. This shows that the musculoskeletal disorders
                                       therapeutics market is highly concentrated thereby leaving less than 40% of the market open for
                                       other players to operate.
                                       Strategic Consolidations Have Led To the Entry of New Players into the Musculoskeletal
                                       Disorders Therapeutics Market
                                       In the past seven years many pharmaceutical companies has improved on their product profiles
                                       with respect to the musculoskeletal disorders therapeutics market. This is due to prominent deals
                                       with the aim of introducing new products with better efficacy and safety profiles into the market. The
                                       acquisitions of Arana therapeutics by Cephalon, Wyeth by Pfizer and Sigma Pharmaceuticals by
                                       Aspen Pharmaceuticals have been the major acquisitions in the musculoskeletal disorders
                                       therapeutics market. These strategic consolidations have allowed the entry of pharmaceutical
                                       companies such as Kyowa Hakko Kirin, Biotie Therapies, Aspen to enter the market. Also,
                                       companies such as Pfizer, Abbott and Merck and Novartis can expand their market coverage due
                                       to these consolidations thereby making the competition even more intense.
                                       These strategic consolidations will help acquirer and licensee companies to diversify their profiles
                                       by entering into musculoskeletal disorders therapeutics market which will in turn make
                                       musculoskeletal disorders therapeutics market more vibrant. These consolidations will also help the
                                       companies to generate revenues thereby increasing the total revenue of the global musculoskeletal
                                       disorders therapeutics market.




Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                   GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                        Page 2
Rheumatoid Arthritis                                                             © GBI Research. This is a licensed product and is not to be photocopied
                                       1         Table of Contents
                                       1   Table of Contents ........................................................................................................................ 3
                                           1.1    List of Tables..................................................................................................................... 5
                                           1.2    List of Figures ................................................................................................................... 8
                                       2   Global Musculoskeletal Disorders Therapeutics Market: Introduction ....................................... 11
                                           2.1    GBI Research Report Guidance ..................................................................................... 12
                                       3   Global Musculoskeletal Disorders Therapeutics Market: Market Overview ............................... 13
                                           3.1    Introduction ..................................................................................................................... 13
                                           3.2    Revenue Forecasts for the Global Musculoskeletal Disorders Therapeutics Market ...... 14
                                              3.2.1    Revenue .................................................................................................................. 14
                                              3.2.2    Annual Cost of Treatment (ACT) ............................................................................. 15
                                              3.2.3    Treatment Usage Patterns ...................................................................................... 16
                                           3.3    Generics in Musculoskeletal Disorders Therapeutics Market.......................................... 21
                                       4   Global Musculoskeletal Disorders Therapeutics Market: Geographical Landscape .................. 22
                                           4.1    Revenue Analysis By Geography ................................................................................... 22
                                           4.2    The US............................................................................................................................ 24
                                              4.2.1    Revenue .................................................................................................................. 24
                                              4.2.2    Annual Cost of Treatment........................................................................................ 26
                                              4.2.3    Treatment Usage Patterns ...................................................................................... 28
                                           4.3    Top Five EU Countries.................................................................................................... 34
                                              4.3.1    Revenue .................................................................................................................. 34
                                              4.3.2    Annual Cost of Treatment........................................................................................ 36
                                              4.3.3    Treatment Usage Patterns ...................................................................................... 38
                                           4.4    Japan .............................................................................................................................. 44
                                              4.4.1    Revenue .................................................................................................................. 44
                                              4.4.2    Annual Cost of Treatment........................................................................................ 46
                                              4.4.3    Treatment Usage Patterns ...................................................................................... 47
                                       5   Global Musculoskeletal Disorders Therapeutics Market: Therapeutic Landscape..................... 53
                                           5.1    Osteoporosis Therapeutics Market ................................................................................. 53
                                              5.1.1    Introduction.............................................................................................................. 53
                                              5.1.2    Revenue .................................................................................................................. 53
                                              5.1.3    Annual Cost of Treatment........................................................................................ 55
                                              5.1.4    Treatment Usage Patterns ...................................................................................... 57
                                              5.1.5    Drivers and Barriers for the Osteoporosis Therapeutics Market .............................. 64
                                              5.1.6    Opportunity and Unmet Need .................................................................................. 65
                                           5.2    Osteoarthritis Therapeutics Market ................................................................................. 66
                                              5.2.1    Introduction.............................................................................................................. 66
                                              5.2.2    Revenue .................................................................................................................. 66
                                              5.2.3    Annual Cost of Treatment........................................................................................ 68
                                              5.2.4    Treatment Usage Patterns ...................................................................................... 69
                                              5.2.5    Drivers and Barriers for the Osteoarthritis Therapeutics Market.............................. 76
                                              5.2.6    Opportunity and Unmet Need .................................................................................. 77
                                           5.3    Rheumatoid Arthritis Therapeutics Market ...................................................................... 78
                                              5.3.1    Introduction.............................................................................................................. 78
                                              5.3.2    Revenue .................................................................................................................. 78
                                              5.3.3    Annual Cost of Treatment........................................................................................ 80
                                              5.3.4    Treatment Usage Patterns ...................................................................................... 82
                                              5.3.5    Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market................... 88
                                              5.3.6    Unmet Need for Rheumatoid Arthritis Therapeutics Market .................................... 89
                                           5.4    Muscular Dystrophy Therapeutics Market....................................................................... 90
                                              5.4.1    Introduction.............................................................................................................. 90
                                              5.4.2    Revenue .................................................................................................................. 90
                                              5.4.3    Annual Cost of Treatment........................................................................................ 92
                                              5.4.4    Treatment Usage Patterns ...................................................................................... 93


Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                                       GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                                                       Page 3
Rheumatoid Arthritis                                                                     © GBI Research. This is a licensed product and is not to be photocopied
                                              5.4.5    Drivers and Barriers for the Muscular Dystrophy Therapeutics Market ................. 100
                                              5.4.6    Unmet Need for Muscular Dystrophy Therapeutics Market ................................... 101
                                       6   Global Musculoskeletal Disorders Therapeutics Market: Pipeline Analysis............................. 102
                                           6.1    Introduction ................................................................................................................... 102
                                              6.1.1    Research and Development Pipeline – Osteoarthritis ........................................... 103
                                              6.1.2    Research and Development Pipeline – Osteoporosis ........................................... 109
                                              6.1.3    Research and Development Pipeline – Rheumatoid Arthritis ................................ 118
                                              6.1.4    Research and Development Pipeline – Muscular Dystrophy................................. 129
                                           6.2    Profiles of Promising Drugs in the Musculoskeletal Disorders Therapeutics Market..... 132
                                              6.2.1    Catena/Sovrima (Idebenone)................................................................................. 132
                                              6.2.2    IPlex(TM) (Mecasermin Rinfabate)........................................................................ 132
                                              6.2.3    CG5503 (Tapentadol ER) ...................................................................................... 133
                                       7   Global Musculoskeletal Disorders Therapeutics Market: Competitive Landscape................... 134
                                           7.1    Evolving competitive landscape .................................................................................... 134
                                              7.1.1    Major Players......................................................................................................... 135
                                           7.2    Market Share Analysis .................................................................................................. 136
                                           7.3    Competitive Profiling ..................................................................................................... 137
                                              7.3.1    Novartis AG ........................................................................................................... 137
                                              7.3.2    Pfizer ..................................................................................................................... 138
                                              7.3.3    Hoffmann-La Roche Ltd. ....................................................................................... 139
                                              7.3.4    Merck & Co., Inc .................................................................................................... 141
                                              7.3.5    Eli Lilly and Company ............................................................................................ 143
                                              7.3.6    Abbott Laboratories ............................................................................................... 145
                                              7.3.7    Johnson & Johnson ............................................................................................... 146
                                              7.3.8    Amgen Inc. ............................................................................................................ 147
                                              7.3.9    Procter & Gamble Company.................................................................................. 149
                                              7.3.10 Bristol-Myers Squibb Company ............................................................................. 150
                                       8   Global Musculoskeletal Disorders Therapeutics Market: M&A Landscape.............................. 152
                                           8.1    Overview ....................................................................................................................... 152
                                              8.1.1    Pfizer Acquires Wyeth ........................................................................................... 153
                                              8.1.2    Cephalon Acquires Arana Therapeutics ................................................................ 153
                                              8.1.3    Aspen Pharmacare Acquires Sigma Pharmaceuticals .......................................... 153
                                           8.2    R&D Licensing Agreements .......................................................................................... 153
                                              8.2.1    Deals by Phase ..................................................................................................... 153
                                              8.2.2    Deals by Geography.............................................................................................. 154
                                              8.2.3    Deals by Value ($) ................................................................................................. 155
                                              8.2.4    Preclinical .............................................................................................................. 156
                                              8.2.5    Phase I .................................................................................................................. 157
                                              8.2.6    Phase II ................................................................................................................. 158
                                              8.2.7    Phase III ................................................................................................................ 159
                                              8.2.8    Approved ............................................................................................................... 160
                                              8.2.9    Marketed Drugs ..................................................................................................... 162
                                       9   Global Musculoskeletal Disorders Therapeutics Market: Appendix ......................................... 163
                                           9.1    Market Definitions ......................................................................................................... 163
                                           9.2    Abbreviations ................................................................................................................ 163
                                           9.3    Research Methodology ................................................................................................. 165
                                              9.3.1    Coverage ............................................................................................................... 165
                                              9.3.2    Secondary Research ............................................................................................. 165
                                              9.3.3    Primary Research.................................................................................................. 166
                                              9.3.4    Forecasts............................................................................................................... 166
                                              9.3.5    Expert Panel Validation ......................................................................................... 169
                                           9.4    Contact Us .................................................................................................................... 169
                                           9.5    Disclaimer ..................................................................................................................... 169
                                           9.6    Sources......................................................................................................................... 169



Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                                      GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                                                     Page 4
Rheumatoid Arthritis                                                                     © GBI Research. This is a licensed product and is not to be photocopied
                                       1.1     List of Tables
                                       Table 1:    Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn),
                                                   2001-2009 ...................................................................................................................... 14
                                       Table 2:    Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn),
                                                   2009-2016 ...................................................................................................................... 14
                                       Table 3:    Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                   2001-2009 ...................................................................................................................... 15
                                       Table 4:    Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                   2009-2016 ...................................................................................................................... 15
                                       Table 5:    Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns
                                                   (Millions), 2001-2009...................................................................................................... 16
                                       Table 6:    Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns
                                                   (Millions), 2009-2016..................................................................................................... 17
                                       Table 7:    Musculoskeletal Disorders Therapeutics Market, Global, Generics Sales Forecast ($bn),
                                                   2009-2016 ...................................................................................................................... 21
                                       Table 8:    Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by
                                                   Geography ($bn), 2001-2009 ......................................................................................... 22
                                       Table 9:    Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by
                                                   Geography ($bn), 2009-2016 ......................................................................................... 23
                                       Table 10:   Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn),
                                                   2001-2009 ...................................................................................................................... 25
                                       Table 11:   Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn),
                                                   2009-2016 ...................................................................................................................... 25
                                       Table 12:   Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                   2001-2009 ...................................................................................................................... 27
                                       Table 13:   Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                   2009-2016 ...................................................................................................................... 27
                                       Table 14:   Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns
                                                   (Millions), 2001-2009...................................................................................................... 28
                                       Table 15:   Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns
                                                   (Millions), 2009-2016...................................................................................................... 29
                                       Table 16:   Musculoskeletal Disorders Therapeutics Market, Top Five EU Countries, Revenue
                                                   Forecasts ($bn), 2001-2009 ........................................................................................... 35
                                       Table 17:   Musculoskeletal Disorders Therapeutics Market, Top Five EU Countries, Revenue
                                                   Forecasts ($bn), 2009-2016 ........................................................................................... 35
                                       Table 18:   Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Annual
                                                   Cost of Treatment ($), 2001-2009 .................................................................................. 37
                                       Table 19:   Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU, Annual
                                                   Cost of Treatment ($), 2009-2016 .................................................................................. 37
                                       Table 20:   Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU,
                                                   Treatment Usage Patterns (Millions), 2001-2009........................................................... 38
                                       Table 21:   Musculoskeletal Disorders Therapeutics Market, Top Five Countries in the EU,
                                                   Treatment Usage Patterns(Millions), 2009-2016............................................................ 39
                                       Table 22:   Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2001-2009 .. 45
                                       Table 23:   Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2009-2016 .. 45
                                       Table 24:    Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                   2001-2009 ...................................................................................................................... 46
                                       Table 25:   Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                   2009-2016 ...................................................................................................................... 46
                                       Table 26:   Musculoskeletal Disorders Therapeutics Market , Japan, Treatment Usage Patterns
                                                   (Millions), 2001-2009...................................................................................................... 47
                                       Table 27:   Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns
                                                   (Millions), 2009-2016...................................................................................................... 48
                                       Table 28:   Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ....................... 54
                                       Table 29:   Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2009-2016 ....................... 54
                                       Table 30:   Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 56
                                       Table 31:   Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 . 56
                                       Table 32:   Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-
                                                   2009 ............................................................................................................................... 58



Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                                       GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                                                       Page 5
Rheumatoid Arthritis                                                                   © GBI Research. This is a licensed product and is not to be photocopied
                                       Table 33: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2009-
                                                 2016 ............................................................................................................................... 59
                                       Table 34: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ....................... 67
                                       Table 35: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2009-2016 ....................... 67
                                       Table 36: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009
                                                 ....................................................................................................................................... 68
                                       Table 37: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 68
                                       Table 38: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2001-
                                                 2009 ............................................................................................................................... 70
                                       Table 39: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2009-
                                                 2016 ............................................................................................................................... 71
                                       Table 40: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ............ 79
                                       Table 41: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2009-2016 ............ 79
                                       Table 42: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-
                                                 2009 ............................................................................................................................... 81
                                       Table 43: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-
                                                 2016 ............................................................................................................................... 81
                                       Table 44: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns, 2001-
                                                 2009 ............................................................................................................................... 83
                                       Table 45: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns, 2009-
                                                 20016 ............................................................................................................................. 83
                                       Table 46: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2001-2009 .............. 91
                                       Table 47: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2009-2016 .............. 91
                                       Table 48: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-
                                                 2009 ............................................................................................................................... 92
                                       Table 49: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-
                                                 2016 ............................................................................................................................... 92
                                       Table 50: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s),
                                                 2001-2009 ...................................................................................................................... 94
                                       Table 51: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s),
                                                 2009-2016 ...................................................................................................................... 95
                                       Table 52: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Discovery Stage
                                                 Molecules, 2010 ........................................................................................................... 104
                                       Table 53: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Preclinical Molecules,
                                                 2010 ............................................................................................................................. 105
                                       Table 54: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase I Molecules,
                                                 2010 ............................................................................................................................. 106
                                       Table 55: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase II Molecules,
                                                 2010 ............................................................................................................................. 107
                                       Table 56: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, Phase III Molecules,
                                                 2010 ............................................................................................................................. 108
                                       Table 57: Musculoskeletal Disorders Therapeutics- Osteoarthritis Pipeline, NDA Filed Molecules,
                                                 2010 ............................................................................................................................. 109
                                       Table 58: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Discovery Stage
                                                 Molecules, 2010 ........................................................................................................... 110
                                       Table 59: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Preclinical Molecules,
                                                 2010 ............................................................................................................................. 110
                                       Table 60: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase I Molecules,
                                                 2010 ............................................................................................................................. 111
                                       Table 61: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase II Molecules,
                                                 2010 ............................................................................................................................. 112
                                       Table 62: Musculoskeletal Disorders Therapeutics- Osteoporosis Pipeline, Phase III Molecules,
                                                 2010 ............................................................................................................................. 115
                                       Table 63: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Discovery Stage
                                                 Molecules, 2010 ........................................................................................................... 119
                                       Table 64: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Preclinical
                                                 Molecules, 2010 ........................................................................................................... 120
                                       Table 65: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase I
                                                 Molecules, 2010 ........................................................................................................... 123
                                       Table 66: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase II
                                                 Molecules, 2010 ........................................................................................................... 125
                                       Table 67: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, Phase III
                                                 Molecules, 2010 ........................................................................................................... 128

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                                         GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                                                         Page 6
Rheumatoid Arthritis                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                       Table 68: Musculoskeletal Disorders Therapeutics- Rheumatoid Arthritis Pipeline, NDA Filed
                                                 Molecules, 2010 ........................................................................................................... 129
                                       Table 69: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Discovery Stage
                                                 Molecules, 2010 ........................................................................................................... 129
                                       Table 70: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Preclinical
                                                 Molecules, 2010 ........................................................................................................... 130
                                       Table 71: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase I
                                                 Molecules, 2010 ........................................................................................................... 130
                                       Table 72: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase II
                                                 Molecules, 2010 ........................................................................................................... 131
                                       Table 73: Musculoskeletal Disorders Therapeutics- Muscular Dystrophy Pipeline, Phase III
                                                 Molecules, 2010 ........................................................................................................... 131
                                       Table 74: Musculoskeletal Disorders Therapeutics Market, Global, Major M&A Deals, 2008-2010
                                                 ..................................................................................................................................... 152
                                       Table 75: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Drugs in the Preclinical Stage, 2008-2010 ................................................................... 156
                                       Table 76: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Drugs in the Phase I, 2008-2010.................................................................................. 157
                                       Table 77: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Drugs in the Phase II, 2008-2010................................................................................. 158
                                       Table 78: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Drugs in the Phase III, 2008-2010................................................................................ 159
                                       Table 79: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Approved Drugs, 2008-2010 ........................................................................................ 160
                                       Table 80: Musculoskeletal Disorders Therapeutics Market, Global, Licensing Agreements for
                                                 Marketed Drugs, 2008-2010 ........................................................................................ 162




Musculoskeletal Disorders Therapeutics to 2016 - Introduction of                                                                        GBIHC032MR / Published OCT 2010
Monoclonal Antibodies with First - in - class Mechanism of
Action to Increase Treatment Options in Osteoporosis and                                                                                                                        Page 7
Rheumatoid Arthritis                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                       1.2       List of Figures
                                       Figure 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn),
                                                  2001-2016 ...................................................................................................................... 14
                                       Figure 2: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                  2001-2016 ...................................................................................................................... 15
                                   
								
To top